Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Other 1 Genitourinary 1

Conditions

Neoplasms 1 Critical Illness 1 Acute Kidney Injury 1

Interventions

Docetaxel 33 Radiosurgery 23 Radiotherapy 21 Sunitinib 20 pembrolizumab 18 Gemcitabine 16 Cisplatin 16 Androgen Antagonists 15 Nivolumab 14 enzalutamide 13 Goserelin 13 Prednisone 12 Leuprolide 12 Blood Specimen Collection 12 Abiraterone Acetate 12 bicalutamide 11 aldesleukin 11 Surveys and Questionnaires 11 Cyclophosphamide 11 Gonadotropin-Releasing Hormone 10 Bevacizumab 10 Multiparametric Magnetic Resonance Imaging 9 Carboplatin 9 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8 Triptorelin Pamoate 8 Radiotherapy, Intensity-Modulated 8 Filgrastim 8 Epirubicin 8 Chemotherapy, Adjuvant 8 Brachytherapy 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Spironolactone × Genitourinary × Clear all

NCT02531412 2017-01-04

SPIROCAN

Instituto Nacional de Cancerologia de Mexico

Phase 2/3 Unknown

Neoplasms, Critical Illness, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡